文献速递甲状腺疾病

ETS因子ETV5激活甲状腺癌中突变型端粒酶逆转录酶启动子

ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.
PubMed 文献 · Thyroid · 2019-10-29

研究结合TCGA数据分析和体外甲状腺细胞模型实验,旨在鉴定甲状腺癌中激活TERT启动子(TERTp)的ETS因子。发现ETV5在甲状腺乳头状癌中高表达,优先结合-124 bp(T) TERTp等位基因并刺激TERT转录,且与FOXE1协同增强TERTp活性,提示ETV5以突变等位基因特异性方式激活TERTp。

要点

  • ETV5在甲状腺乳头状癌中高表达并优先结合突变型TERTp等位基因。
  • ETV5与FOXE1协同增强TERTp活性,部分解释FOXE1为甲状腺癌风险遗传决定因素。
  • 激活突变型TERTp的ETS因子因癌种而异,甲状腺癌中ETV5具等位基因特异性。

核心结论

  • 激活突变型TERTp的ETS因子在不同癌种间存在差异,甲状腺癌中ETV5首次被证实对TERTp具有突变等位基因特异性亲和力。

研究设计与样本

  • 研究结合TCGA数据集的硅分析以及体外甲状腺细胞模型的定量逆转录PCR、免疫沉淀、染色质免疫沉淀和基因报告基因实验。

主要发现

  • TCGA数据集中甲状腺乳头状癌及甲状腺癌细胞系模型均显示ETV5高表达。
  • ETV5优先结合-124 bp(T) TERTp等位基因并在缺乏GABP活性的甲状腺癌细胞中刺激TERT转录。
  • ETV5与转录因子FOXE1功能协同,进一步增强TERTp活性。

临床怎么用

  • ETV5可能作为甲状腺癌中突变型TERTp激活的关键因子,为理解TERTp突变与BRAF/RAS突变协同致癌机制提供线索。

局限性

  • 研究主要基于体外细胞模型和硅分析,未在体内或临床样本中验证ETV5的功能依赖性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Co-occurrence of TERT (telomerase reverse transcriptase) promoter (TERTp) mutations with BRAF/RAS mutations is associated with significantly more aggressive thyroid cancer. TERTp mutations are hypothesized to generate de novo binding sites for ETS transcription factors, which are themselves activated by BRAF/RAS-stimulated MEK-ERK activity. To date, a detailed study of this mechanism has been limited to only a few cancer types, and we hypothesized that ETS factors involved in TERTp activation could vary between different cancers. Methodology: Here we sought to identify ETS factor(s) required for TERTp activation in thyroid cancer, using a combination of in silico analyses of TCGA data, and experimentation using in vitro thyroid cell models analyzed by quantitative reverse transcription-PCR, immunoprecipitation (IP), chromatin IP, and gene reporter assays. Results: We found that ETV5 was abundantly expressed in papillary thyroid cancers from the TCGA data set, and in thyroid cancer cell line models. Furthermore, ETV5 was found to preferentially bind to the -124 bp(T) TERTp allele and stimulate TERT transcription in thyroid cancer cells devoid of GA binding protein transcription factor (GABP) activity. We also found that ETV5 functionally cooperates with the transcription factor FOXE1 to further enhance TERTp activity, a mechanism that may at least partially explain why FOXE1 represents a significant genetic determinant of thyroid cancer risk. Conclusions: ETS factors that activate mutant TERTp vary between cancer types, and here we show for the first time that ETV5 demonstrates mutant allele-specific affinity for TERTp in thyroid cancer, a property that has previously only been attributable to GABP.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bullock M, Lim G, Zhu Y, et al. ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer. Thyroid. 2019. PMID: 31452441. doi:10.1089/thy.2018.0314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。